Atlas Trials

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Clinical trial NCT05270889 · UNKNOWN

Trial details

NCT number
NCT05270889
Sponsor
Yonsei University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Gastric Cancer
Start date
2022-04-01
Primary completion
2024-06-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.